Reckitt to pay $1.4 billion to end opioid addiction treatment probes

Reckitt Benckiser has agreed to pay up to $1.4 billion to end U.S. federal investigations into the marketing of an opioid addiction treatment by its former business Indivior, lifting a cloud that has been hanging over the British company for years.